Wednesday, October 4, 2023
Wednesday, October 4, 2023

Contact: 561.316.3330

Compact Proton Therapy System by Hitachi at Shonan Kamakura Advanced Medical Center

Compact Proton Therapy System-Hitachi, Ltd. (TSE: 6501) has announced that “Shonan Kamakura Advanced Medical Center” at Shonan Kamakura General Hospital of Tokushukai Medical Group, where Hitachi’s compact proton therapy system (hereafter, “the system”) has been installed, has commenced treatment with the system on 31 January 2022. This is the first order for Hitachi’s dedicated compact proton therapy system.

Shonan Kamakura Advanced Medical Center is a medical facility providing comprehensive cancer treatment, including advanced radiotherapy, built adjacent to the site of Shonan Kamakura General Hospital by Tokushukai Group Medical Corporation, which operates approximately 400 medical facilities and nursing homes throughout Japan.

Until now, there have been no proton therapy facilities in Kanagawa Prefecture, where the center is located, but the compact proton therapy system, with its reduced footprint, makes it possible to install a proton therapy facility on a limited site close to the city center.

Features of the installed system

In response to the growing worldwide demand for smaller proton therapy systems, Hitachi has developed the proton therapy system, which is specifically designed for a single treatment room. The system is a compact proton therapy system which, by optimizing the layout of the machine, reduces the installation area to about 70% of that of conventional solutions, making it possible to install the system on a limited site in an urban area and reducing the cost and time involved in its installation.

It is equipped with advanced technologies such as spot scanning irradiation technology, which allows the proton beam to be delivered according to the shape of the cancer, a 360degree rotating gantry with cone-beam CT(1) for high-precision positioning, and Real-time image Gated Proton Therapy (RGPT)(2), making it both compact and highly functional.

Hitachi is committed to accelerating the global development of particle therapy system and contributing to cancer treatment around the world, as well as to further expanding its healthcare services.

(1) Cone beam CT provides three-dimensional anatomical images of patients, at isocenter immediately prior to being treated. Information on the location of bone is obtained from traditional orthogonal x-rays and the motion of tumors is captured by RGPT. These are then combined with the ability to identify healthy tissue surrounding a tumor, particularly the location and shape of soft tissue, via Cone beam CT.

(2) RGPT allows real-time beam irradiation to the tumor while compensating for movement associated with respiration. This technology was collaboratively developed between Hokkaido University and Hitachi, and supported by the Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST) of the Japan Society for the Promotion of Science.

Overview of Particle Therapy

Particle Therapy is an advanced type of cancer radiotherapy. Protons extracted from hydrogen atoms, or carbon ions are accelerated up to 70% of the speed of light. This energy is concentrated directly on the tumor while minimizing radiation dose to surrounding healthy tissue. Particle therapy improves the quality of life for cancer patients since the patient experiences no pain during treatment and the procedure has very few side effects compared to that of traditional radiotherapy. In most cases, patients can continue with their normal daily activities while undergoing treatment.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Ariceum Therapeutics’ Targeted Radiopharmaceutical 177Lu-satoreotide Exhibits Promising Clinical Response and Good Tolerability Profile in Patients with Advanced Neuroendocrine Tumours

Satoreotide combines Ariceum’s proprietary peptide satoreotide - a first-in-class and best-in-class antagonist of the somatostatin receptor 2 (SSTR2) - with the radioactive isotope ‘payload’ 177Lutetium. SSTR2 is a cell surface protein often overexpressed in certain cancers, including NETs and small cell lung cancer (SCLC).

New Hot Start Isothermal Mixes Boost Sensitivity, Specificity, and Speed of DNA Target Detection

Isothermal mixes are important in a range of isothermal amplification applications, including whole genome amplification, point-of-care assay development and testing, and strand displacement amplification for synthetic biology. However, a common issue with isothermal mixes is non-specific amplification — where primers bind to unintended DNA targets — because amplification often takes place at a fixed temperature which may favour non-specific primer interactions, contrary to PCR. Isothermal mixes can also lead to primer dimer formation, where primers associate with each other and are extended by the polymerase.

Branded Legacy Invests Heavily in Innovation and Growth with $540,000 Expansion

This strategic initiative underscores Branded Legacy's unwavering commitment to innovation, quality, and customer satisfaction. The expansion project is set to infuse over $500,000 worth of inventory into the company, reinforcing its position as a leader in the market.

Cue Biopharma Completes Patient Enrollment in Ph1b Head & Neck Cancer Trial

“Completing the enrollment of the recommended phase 2 dose patient expansion cohort is an important milestone as the data from this trial guides further development plans and associated discussions with the Food and Drug Administration (FDA),” said Daniel Passeri, chief executive officer of Cue Biopharma.

Revvity Expands Access to Base Editing Technology with Aim to Accelerate Discovery to Cure

Michelle Fraser, head of cell and gene therapy at Revvity, underscores the importance of providing broad access to this technology: "Base editing has been extensively demonstrated in numerous studies to safely and precisely control the correction of single base changes at multiple target sites, simultaneously. This streamlined approach simplifies complex multi-gene editing, holding great promise for the development of new cell therapies targeting rare inherited genetic diseases, cancer, and in the creation of universal donor cells as the foundation of allogeneic cell therapies."

By using this website you agree to accept Medical Device News Magazine Privacy Policy